Published in Cancer Res on June 15, 2001
A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Pathol (2009) 2.24
Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol (2004) 1.88
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis (2002) 1.05
Characterization of flavin-based fluorescent proteins: an emerging class of fluorescent reporters. PLoS One (2013) 0.87
Directed evolution of bright mutants of an oxygen-independent flavin-binding fluorescent protein from Pseudomonas putida. J Biol Eng (2012) 0.82
NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence. Bioconjug Chem (2016) 0.82
Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. J Control Release (2013) 0.81
A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level. EMBO J (2015) 0.80
Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts. BMC Biotechnol (2001) 0.80
Regulation of Three Nitrogenase Gene Clusters in the Cyanobacterium Anabaena variabilis ATCC 29413. Life (Basel) (2014) 0.78
Tracking in vitro and in vivo siRNA electrotransfer in tumor cells. J RNAi Gene Silencing (2008) 0.78
A lacZ Reporter-Based Strategy for Rapid Expression Analysis and Target Validation of Mycobacterium tuberculosis Latent Infection Genes. Curr Microbiol (2015) 0.77
Direct visualization of the phenotype of hypoxic tumor cells at single cell resolution in vivo using a new hypoxia probe. Intravital (2016) 0.76
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors. Viruses (2016) 0.75
TRIzol and Alu qPCR-based quantification of metastatic seeding within the skeleton. Sci Rep (2015) 0.75
A genetically encoded biosensor for visualizing hypoxia responses in vivo. Biol Open (2016) 0.75
Nanokit for single-cell electrochemical analyses. Proc Natl Acad Sci U S A (2016) 0.75
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Electrochemotherapy in treatment of tumours. Eur J Surg Oncol (2007) 2.51
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11
Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res (1995) 1.85
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J (1998) 1.61
Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer (2008) 1.53
Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat (2011) 1.50
Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol (2001) 1.48
An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed (1993) 1.45
Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer (2000) 1.44
Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin. Hum Gene Ther (2008) 1.39
Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol (2001) 1.34
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res (1997) 1.31
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol (2008) 1.19
Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res (2000) 1.19
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer (1998) 1.10
Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input function. Magn Reson Med (2012) 1.09
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther (2002) 1.02
Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol (1997) 1.02
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer (2002) 1.01
The use of ketamine plus diazepam anaesthesia to increase the radiosensitivity of a C3H mouse mammary adenocarcinoma in hyperbaric oxygen. Br J Radiol (1984) 1.01
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review. Tumori (2000) 0.98
An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections. J Microsc (2010) 0.98
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer (2010) 0.97
The energy metabolism of RIF-1 tumours following hydralazine. Radiother Oncol (1990) 0.96
Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett (1997) 0.95
Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res (2000) 0.93
Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther (2000) 0.93
Hypoxia response elements. Oncol Res (1997) 0.91
Muscle gene electrotransfer is increased by the antioxidant tempol in mice. Gene Ther (2011) 0.91
Reduced tumor oxygenation by treatment with vinblastine. Cancer Res (2001) 0.90
Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions. Mol Cancer Ther (2001) 0.90
Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm. J Microsc (2008) 0.90
The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood (2000) 0.90
Use of low molecular weight heparin in pregnancy. Thromb Haemost (1992) 0.88
Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys (2000) 0.88
The combined measurement of blood flow and metabolism in RIF-1 tumours in vivo. A study using H2 flow and 31P NMR spectroscopy. NMR Biomed (1990) 0.88
The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer (1999) 0.88
Improved photo-CIDNP methods for studying protein structure and folding. J Biomol NMR (2000) 0.87
In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer (2003) 0.87
Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol (1998) 0.87
Can gene therapy overcome the problem of hypoxia in radiotherapy? J Radiat Res (2000) 0.87
Electrochemotherapy of mouse sarcoma tumors using electric pulse trains with repetition frequencies of 1 Hz and 5 kHz. J Membr Biol (2010) 0.86
Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsiveness. Anticancer Drugs (1996) 0.85
Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography. J Chromatogr A (1995) 0.85
Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. Br J Cancer (1993) 0.85
Semi-automated software for the three-dimensional delineation of complex vascular networks. J Microsc (2003) 0.84
Efficient electrotransfection into canine muscle. Technol Cancer Res Treat (2008) 0.84
The effect of the histological properties of tumors on transfection efficiency of electrically assisted gene delivery to solid tumors in mice. Gene Ther (2007) 0.84
MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther (2010) 0.84
Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Analysis of the binding characteristics and mitogenic properties of protein S on human vascular smooth muscle cells. Biochem J (1995) 0.83
Determination of platinum in tumour tissues after cisplatin therapy by electrothermal atomic absorption spectrometry. J Pharm Biomed Anal (1997) 0.83
Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int J Radiat Biol (2002) 0.82
The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest (1995) 0.82
Electrochemotherapy of tumours. Curr Oncol (2009) 0.82
In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer. Cancer Gene Ther (2010) 0.81
Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28. Cancer Gene Ther (2013) 0.81
Gene delivery to hypoxic cells in vitro. Br J Cancer (2000) 0.79
Electrochemotherapy: potentiation of local antitumour effectiveness of cisplatin in dogs and cats. Anticancer Res (2001) 0.79
Effect of endothelin-1 and sarafotoxin S6c on blood flow in a rat tumor. J Cardiovasc Pharmacol (1995) 0.78
Blood perfusion of subcutaneous tumours in mice following the application of low-level direct electric current. Adv Exp Med Biol (1999) 0.78
Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol. Br J Cancer (2004) 0.78
Tumour blood flow modification by endothelin-related peptides in the rat HSN fibrosarcoma. Br J Cancer Suppl (1996) 0.78
Evaluation of the use of the luciferase-reporter-gene system for gene-regulation studies involving cyclic AMP-elevating agents. Biochem J (1995) 0.78
The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. Br J Cancer (2005) 0.78
Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI. Methods (2011) 0.78
Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer (1997) 0.77
Thrombin activates transcription factors sp1, NF-kappaB, and CREB: importance of the use of phosphatase inhibitors during nuclear protein extraction for the assessment of transcription factor DNA-binding activities. Anal Biochem (1999) 0.76
Electrochemotherapy of solid tumors--preclinical and clinical experience. Conf Proc IEEE Eng Med Biol Soc (2011) 0.76
A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: influence of tumour size on angiotensin II response. Int J Cancer (1996) 0.76
Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer (1999) 0.76
An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. Br J Pharmacol (2014) 0.76
The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncol (1995) 0.76
Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin - long term results. Neoplasma (2005) 0.76
A mathematical model of the vascular supply of tumors. Microvasc Res (1996) 0.75
Evidence for cultured human vascular smooth muscle cell heterogeneity: isolation of clonal cells and study of their growth characteristics. Thromb Haemost (1996) 0.75
Effect of vinblastine on cell membrane fluidity in vinblastine-sensitive and -resistant HeLa cells. Cancer Lett (1998) 0.75
Pharmacological manipulation of blood flow. BJR Suppl (1992) 0.75
Use of nitric acid in sample pretreatment for determination of trace elements in various biological samples by ETAAS. J Pharm Biomed Anal (2000) 0.75
New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. Cytokine (1997) 0.75